Skip to main content

Table 3 Patient-reported QOL results

From: Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes

  Baseline Follow Up Mean Change at 1 Year after Treatment Mean Annualized Change after 1 Year
QOL Measure No. of Patients Median (Range) Mean ± SD No. of Patients No. of Visits Value (95% CI) P-valuea Value (95% CI) P-valuea
EPIC Bowel 164 96 (61–100) 93.4 ± 8.5 100 183 −5.4 (−8.2, −2.5) < 0.001 −1.2 (−5.2, 2.9) 0.57
IPSS 178 6 (0–28) 8.7 ± 6.6 130 241 0.5 (−0.7, 1.8) 0.40 −0.5 (−1.9, 1.0) 0.54
IPSS Bother 173 2 (1–7) 2.5 ± 1.4 125 221 0.3 (−0.1, 0.7) 0.12 −0.2 (−0.6, 0.2) 0.32
Nocturia 181 1 (0–8) 1.8 ± 1.5 123 217 0.3 (−0.0, 0.5) 0.077 −0.2 (−0.5, 0.2) 0.33
SHIMa 107 18 (0–25) 16.5 ± 7.1 66 123 −3.7 (−5.9, −1.4) 0.001 1.8 (−1.3, 5.0) 0.25
  1. aOnly assessed in patients not on androgen deprivation therapy